Yes, Gilead put superhigh prices on hep C drugs, but what can you do? Senators ask

Eric Palmer

After 18 months spent slicing and dicing 20,000 pages of Sciences documents and emails, a Senate investigation concluded that the drugmaker put very high price tags on its hep C cures Sovaldi and Harvoni, knowing full well that would keep some patients in need from affording them. Now the Senate sponsors of the inquiry are asking payers and public, based on what was learned, just what can the government do to discourage untenable drug without stepping all over pharma innovation.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS